Relmada Therapeutics (RLMD) Net Income Attributable to Noncontrolling Interests (2021 - 2022)
Relmada Therapeutics (RLMD) posted Net Income Attributable to Noncontrolling Interests of -$39.75 million for Q1 2022, compared with -$22.22 million a year earlier.
Powered by 
Analysis
Relmada Therapeutics (RLMD) Net Income Attributable to Noncontrolling Interests (2021 - 2022) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCI Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,348.13 Bn | 1,321.74 Bn | 20.46 Bn | - |
| 2 | Johnson & Johnson | 675.90 Bn | 595.76 Bn | 17.30 Bn | - |
| 3 | AbbVie | 519.45 Bn | 487.50 Bn | 13.12 Bn | 2.00 Mn |
| 4 | Merck | 364.95 Bn | 327.95 Bn | 13.19 Bn | 2.00 Mn |
| 5 | Novartis Ag | 311.58 Bn | 285.16 Bn | - | - |
| 6 | Astrazeneca | 289.34 Bn | 262.94 Bn | 13.26 Bn | -1.00 Mn |
| 7 | Amgen | 251.64 Bn | 203.30 Bn | 7.58 Bn | - |
| 8 | Gilead Sciences | 212.05 Bn | 187.07 Bn | 6.73 Bn | - |
| 9 | Pfizer | 167.35 Bn | 115.00 Bn | 12.56 Bn | 10.00 Mn |
| 10 | Relmada Therapeutics | 455.48 Mn | -103.11 Mn | - | - |
API Access
Relmada Therapeutics Net Income Attributable to Noncontrolling Interests API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=income-from-non-controlling-interests&ticker=RLMD&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "income-from-non-controlling-interests", "ticker": "RLMD", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=income-from-non-controlling-interests&ticker=RLMD&period=max&api_key=YOUR_API_KEY");
const data = await res.json();